Chimerix (CMRX) Receiving Critical Press Coverage, Study Shows
Press coverage about Chimerix (NASDAQ:CMRX) has been trending negative on Wednesday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Chimerix earned a news impact score of -0.39 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 100 out of 100, indicating that recent press coverage is extremely likely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Chimerix Inc (CMRX) Shares Needle Moving -0.75% – Financial News Review (finnewsreview.com)
- Chimerix, Inc. (CMRX) Downgraded to “Sell” at Zacks Investment Research (americanbankingnews.com)
- Dick’s Sporting Goods Inc (DKS) Stake Raised by Lazard Asset Management LLC (footballhebdo.com)
- Cirrus Logic, Inc. (CRUS) Shares Sold by TIAA CREF Investment Management LLC (healthcaremenu.net)
- Comparing Price Charts: Eros International Plc (EROS), Chimerix, Inc. (CMRX) – StockNewsMagazine (stocknewsmagazine.com)
Shares of Chimerix (CMRX) opened at 5.21 on Wednesday. The stock’s 50 day moving average is $4.93 and its 200-day moving average is $5.38. The stock’s market cap is $243.05 million. Chimerix has a 12-month low of $3.66 and a 12-month high of $6.64.
Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by $0.01. The firm had revenue of $1.08 million for the quarter, compared to the consensus estimate of $1.56 million. Chimerix had a negative return on equity of 24.07% and a negative net margin of 1,221.34%. Equities analysts expect that Chimerix will post ($1.73) EPS for the current year.
A number of equities research analysts have recently commented on the stock. Cowen and Company reiterated a “hold” rating and set a $6.00 price target on shares of Chimerix in a report on Friday, April 28th. FBR & Co reiterated a “hold” rating and set a $7.00 price target on shares of Chimerix in a report on Monday, May 1st. Finally, Zacks Investment Research cut shares of Chimerix from a “hold” rating to a “sell” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $7.55.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.